EUVIMEDEUVIMED entdecken
Crossref

Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3

Zhihai Wu, Jiayi Zhong, Chengcheng Xu, Chengkuan Zhao, Qin Yang iD, Lili Zhao, Chaoxian Lin iD, Shuyao Zhang iD, Junyong Zhong

American Journal of Physiology-Gastrointestinal and Liver Physiology · 01.05.2026 · 330 (5) · G615-G632

DOI: 10.1152/ajpgi.00323.2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, erschienen am 01.05.2026. Verfasst von Zhihai Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Longgang Central Hospital of Shenzhen, Shenzhen, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Galectin 3, T-Lymphocytes, Lymphocyte Activation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Guangzhou Science, Technology and Innovation Commission (Bureau of Science and Information Technology of Guangzhou Municipality), Guangdong Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study identifies the V-set domain-containing T-cell activation inhibitor 1 (VTCN1)–galectin-3 axis as a key immunosuppressive pathway in colorectal cancer (CRC). We show that inhibiting VTCN1 downregulates galectin-3 in T cells, reversing their dysfunction and reactivating antitumor immunity. Therapeutically, the VTCN1 inhibitor SGN-B7H4 restricted tumor progression by enhancing T-cell activity and impairing cancer cell proliferation, migration, and invasion. These findings reveal a novel immune checkpoint mechanism and establish VTCN1 as a promising target to overcome immunotherapy resistance in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGalectin 3T-LymphocytesLymphocyte ActivationHumansAnimalsCell ProliferationMiceCell Line, TumorBlood ProteinsGalectins

Stichwörter der Autor:innen

VTCN1colorectal cancergalectin-3immunosuppressive microenvironmenttumor-immune interactions

Substanzen

Galectin 3LGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • Department of Oncology, Longgang Central Hospital of Shenzhen, Shenzhen, People's Republic of China.
  • Shantou University Medical College, Shantou, People's Republic of China.
  • Department of Pharmacy, Guangzhou Red Cross Hospital of Jinan University, Guangzhou, People's Republic of China.
  • Department of Pharmacy, Shantou Chaonan Minsheng Hospital, Shantou, People's Republic of China.

ORCID-Profile: Qin Yang, Chaoxian Lin, Shuyao Zhang

Förderung

  • Guangzhou Science, Technology and Innovation Commission (Bureau of Science and Information Technology of Guangzhou Municipality)
  • Guangdong Pharmaceutical Association

Zitieren

APA

Wu, Z., Zhong, J., Xu, C., Zhao, C., Yang, Q., Zhao, L., Lin, C., Zhang, S., & Zhong, J. (2026). Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3. American Journal of Physiology-Gastrointestinal and Liver Physiology, 330(5), G615-G632. https://doi.org/10.1152/ajpgi.00323.2025

Vancouver

Wu Z, Zhong J, Xu C, Zhao C, Yang Q, Zhao L, et al. Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2026;330(5):G615-G632. doi:10.1152/ajpgi.00323.2025

BibTeX
@article{Wu2026,
  author = {Wu, Zhihai and Zhong, Jiayi and Xu, Chengcheng and Zhao, Chengkuan and Yang, Qin and Zhao, Lili and Lin, Chaoxian and Zhang, Shuyao and Zhong, Junyong},
  title = {Inhibiting VTCN1 overcomes immunosuppression in colorectal cancer to activate T cells via galectin-3},
  journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
  year = {2026},
  volume = {330},
  number = {5},
  pages = {G615--G632},
  doi = {10.1152/ajpgi.00323.2025}
}
Kostenlos starten →